Curriculum Vitaes

Keiko Hikino

  (曳野 圭子)

Profile Information

Affiliation
Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Tokyo, Japan
Visiting Research Scientist, Laboratory for Pharmacogenomics, RIKEN, Yokohama, JAPAN
Department of Statistical and Translational Genetics, Center for Genomic Medicine, Fujita Health University
Visiting Research Scientist, Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan
Degree
MD(Shimane University, Japan)
PhD(Apr, 2020, Yokohama City University, Japan)

Researcher number
10789580
ORCID ID
 https://orcid.org/0000-0002-4852-2401
J-GLOBAL ID
201901008820546985
researchmap Member ID
B000373995

Papers

 40
  • Kohei Saito, Hsing-Fang Lu, Tatsuhide Inoue, Takeshi Usui, Toshihiro Shirai, Tatsuo Ogawa, Rieko Kosugi, Chika Kyo, Keiko Hikino, Yun Li, Momoko Horikoshi, Hiroshi Itoh, Kaori Hayashi, Toshio Shimada, Koichi Ozaki, Issei Tanaka, Wen-Ling Liao, Yen-Ting Chang, Ting-Yuan Liu, Fuu-Jen Tsai, Chikashi Terao
    Communications Biology, Sep 30, 2026  Peer-reviewed
  • Ludmila Prokunina-Olsson, Oscar Florez-Vargas, Michael G. Levin, Diptavo Dutta, Charles E. Breeze, Lauren M. Hurwitz, Wusheng Yan, Philippe Lamy, Brenen W. Papenberg, Kevin Wang, Chia-Han Lee, Roger L. Milne, Jian Gu, Caroline Y. Um, Vijai Joseph, Helena Furberg, Florence Le Calvez-Kelm, Adriana Lori, Parichoy Pal Choudhury, Nina Afshar, Manolis Kogevinas, Kenneth Offit, Sita H. Vermeulen, Evangelina López de Maturana, Demetrius Albanes, Mark P. Purdue, Victoria K. Cortessis, Margaret R. Karagas, Charles Kooperberg, Marc Bjurlin, Deborah A. Tadesse, Steven C. Moore, Wen-Yi Huang, Christopher A. Haiman, Mariana C. Stern, A. Heather Eliassen, Lorelei A. Mucci, Katja K. Aben, Tessel E. Galesloot, Tatjana Simic, Dejan Dragicevic, Arndt Hartmann, Veronika Weyerer, Danijel Sikic, Gregers G. Hermann, Karin Mogensen, Marcus Horstmann, Marc-Oliver Grimm, Roman Nawroth, Tobias Maurer, Ellen C. Zwarthoff, Kim E. M. van Kessel, Lars Dyrskjøt, Torben Ørntoft, Sia Viborg Lindskrog, Frederik Prip, Jørgen Bjerggaard Jensen, Ulrika Segersten, Per-Uno Malmström, Astrid C. Petersen, Anurag Verma, Soichiro Yoshino, Keiko Hikino, Chikashi Terao, Thorunn Rafnar, Koichi Matsuda, Taro Shuin, Montserrat Garcia-Closas, Francisco X. Real, Lambertus A. Kiemeney, Stephen J. Chanock, Núria Malats, Debra T. Silverman, Lars Dyrskjot, Nathaniel Rothman, Scott M. Damrauer, Stella Koutros, Jeffrey S. Damrauer
    Nature Communications, Aug 8, 2026  Peer-reviewed
  • Shunsuke Uchiyama, Takeo Saito, Xiaoxi Liu, Yuki Ishikawa, Keiko Hikino, Masashi Ikeda, Giulio Genovese, Nakao Iwata, Chikashi Terao
    Molecular Psychiatry, May, 2026  Peer-reviewed
  • Fei-Fei Cheng, Xiaoxi Liu, Hao Mi, Lizhong Wang, Ruilei Ma, Yazhou Guo, Julia Sidorenko, Chen Jiang, Tania Islam, Akira Meguro, Keiko Hikino, Yuki Ishikawa, Senwei Tang, Teng Li, Ruoyan Chen, Likun Wang, Reedik Mägi, Andres Metspalu, Estonian Biobank Research Team, Lili Milani, Tõnu Esko, Mari Nelis, Georgi Hudjashov, 23andMe Research Team, Adam Auton, Alan Kwong, Anjali J. Shastri, Barry Hicks, Catherine H. Weldon, David A. Hinds, Emily DelloRusso, Emily M. Rios, Joyce Y. Tung, Kahsaia de Brito, Katelyn Kukar Bond, Keng-Han Lin, Matthew H. McIntyre, Matthew J. Kmiecik, Qiaojuan Jane Su, Robert K. Bell, Sayantan Das, Shubham Saini, Stella Aslibekyan, Vinh Tran, Wanwan Xu, Alisa P. Lehman, Noura S. Abul-Husn, R. Ryanne Wu, Rebecca M. K. Berns, Ruth I. Tennen, Stacey B. Detweiler
    Nature Genetics, Apr 20, 2026  Peer-reviewed
  • Claire Moore, Melissa S Bourque, Andreas Halman, José A G Agúndez, Cynthia A Prows, Keiko Hikino, Matthias Schwab, Carolyn J Oxencis, Dharmisha Chauhan, Meta H M Diekstra, Susie E Long, Gillian C Bell, Andrea Gaedigk, Michelle Whirl-Carrillo, Teri E Klein, Kelly E Caudle, Rachel Conyers
    Clinical pharmacology and therapeutics, Apr 14, 2026  Peer-reviewed
    5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. Most of the 5-HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).

Research Projects

 7